Related Experiment Video
Updated: Jan 31, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
[Biosimilars in oncology. Focus on SB3 studies.]
Marzia Del Re1, Lucia Del Mastro2
1Dipartimento di Medicina Clinica e Sperimentale, Azienda Ospedaliero-Universitaria Pisana, Pisa.
Abstract:
A phase III study compared SB3, a trastuzumab biosimilar, with trastuzumab originator in 800 HER2 positive breast cancer patients undergoing neoadjuvant chemotherapy. The aim of the study was to demonstrate the equivalence between the two drugs in terms of pathological complete responses. The total pathologic complete response rates were 51.7% and 42.0% with SB3 and trastuzumab, respectively. Equivalence for efficacy was demonstrated between SB3 and trastuzumab. Safety and immunogenicity were comparable.
More Related Videos
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Focusing of Light in the Eye
Coping Strategies: Problem Focused
For example, consider a student who struggles to understand their...
Coping Strategies: Emotion Focused
Methods of Documentation IV: Focus Charting
It typically involves three columns for recording information:
Techniques of Therapeutic Communication II: Focusing, Paraphrasing, and Summarizing
This therapeutic technique can also be used when a patient brings up pertinent information during a health-related conversation. The...

